Metin Yeşiltepe

The paper develops NN-800s, trimeric nanobodies that inhibit TNFα and cross the BBB via TfR1, showing potent activity and safety in preclinical models.

This study uses a FDD-KI rat model to show that vascular amyloid deposition, neuroinflammation, and white matter damage contribute to motor dysfunction in Familial Danish Dementia.

This study develops humanized TfR1 and Tf gene-replacement rats to evaluate BBB transport of human-specific therapeutics, showing viability and partial functional compensation.

This paper develops humanized TfR1-targeting nanobodies (NewroBus) that cross the BBB and deliver therapeutic payloads to the CNS.

The paper shows BRI2 regulates TREM2 processing in microglia, affecting Alzheimer's disease risk, and suggests BRI2 as a therapeutic target.